Drug Trial Radar · NCT04657289
A Study of the Efficacy, Safety, and Pharmacokinetics of a 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
Last checked: Nov 20, 2026Latest source record: Oct 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
451
Actual
Start
Jul 14, 2021
Primary completion
Feb 4, 2027
Study completion Feb 4, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Dec 8, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Study WR42221 is a Phase IIIb, global, multicenter, randomized, visual assessor-masked study designed to assess the efficacy, safety, and pharmacokinetics of the Port Delivery System with ranibizumab (PDS) 100 mg/mL delivered every 36 weeks (Q36W) compared with every 24 weeks (Q24W) in patients with neovascular age-related macular degeneration (nAMD).
Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
Interventions
RanibizumabDrug
Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
Port Delivery System with RanibizumabDevice
Arm A: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 36-week intervals Arm B: Participants will receive ranibizumab delivered through the PDS implant with 100 mg/mL in the study eye on Day 1 and receive refill-exchanges at fixed 24-week intervals
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in Best-corrected visual acuity (BCVA) score averaged over Weeks 68 and 72, as assessed using the ETDRS chart starting at a distance of 4 metersTime frame: Baseline to Week 72
Locations
104 sites in 16 countries. Site status is shown where the registry gives one.
Centro Oftalmologico Dr. Charles S.A.
Capital Federal, Argentina
Oftalmos
Capital Federal, Argentina
Grupo Laser Vision
Rosario, Argentina
Eyeclinic Albury Wodonga
Albury, New South Wales, Australia
Eye and Retina Consultants
Hurstville, New South Wales, Australia
Retina Associates Liverpool
Liverpool, New South Wales, Australia
Retina and Macula Specialists
Miranda, New South Wales, Australia
Sydney Eye Hospital
Sydney, New South Wales, Australia
Sydney Retina Clinic and Day Surgery
Sydney, New South Wales, Australia
Queensland Eye Institute
Woolloongabba, Queensland, Australia
Centre For Eye Research Australia
East Melbourne, Victoria, Australia
Retina Specialists Victoria
Rowville, Victoria, Australia
The Lions Eye Institute
Nedlands, Western Australia, Australia
LKH-Univ.Klinikum Graz
Graz, Austria
Medizinische Universitat Wien
Vienna, Austria
UZ Leuven Gasthuisberg
Leuven, Belgium
Hospital das Clinicas - UFRGS
Porto Alegre, Rio Grande do Sul, Brazil
Botelho Hospital da Visao
Blumenau, Santa Catarina, Brazil
Retina Clinic
São Paulo, São Paulo, Brazil
Universidade Federal de Sao Paulo - UNIFESPX
São Paulo, São Paulo, Brazil
Instituto da Visao IPEPO
São Paulo, São Paulo, Brazil
Hosp de Olhos de Sorocaba
Sorocaba, São Paulo, Brazil
Centre Retine Gallien
Bordeaux, France
Hopital de la croix rousse
Lyon, France
Centre Paradis Monticelli
Marseille, France
Hopital Lariboisiere
Paris, France
Fondation Rothschild
Paris, France
Universitatsklinikum Bonn
Bonn, Germany
Universitatsklinikum Koln
Cologne, Germany
Medizinische Universitat Lausitz ? Carl Thiem
Cottbus, Germany
Universitätsklinikum Freiburg, Klinik für Augenheilkunde
Freiburg im Breisgau, Germany
Universitatsklinikum Hamburg-Eppendorf
Hamburg, Germany
Klinikum der Stadt Ludwigshafen am Rhein gGmbH
Ludwigshafen, Germany
LMU Klinikum der Universitat, Augenklinik
München, Germany
Augenabteilung am St. Franziskus-Hospital
Münster, Germany
Universitatsklinikum Munster
Münster, Germany
Knappschaftsklinikum Saar GmbH
Sulzbach, Germany
Universitatsklinikum Tubingen
Tübingen, Germany
Universitatsklinikum Ulm, Augenklinik und Poliklinik
Ulm, Germany
Rambam Medical Center
Haifa, Israel
Showing 40 of 104 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.